Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-021-00544-9 http://scihub22266oqcxt.onion/10.1038/s41577-021-00544-9 33795856!8014893!33795856     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Immunol 2021 ; 21 (5): 330-335 Nephropedia Template TP {{tp|p=33795856|t=2021. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination |pdf=|usr=}}{{33795856}} gab.com Text Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33795856 #FOAvip When vaccines are in limited supply, expanding the number of people who receive some vaccine, such as by halving doses or increasing the interval between doses, can reduce disease and mortality compared with concentrating available vaccine doses in a subset of the population. A corollary of such dose-sparing strategies is that the vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine-escape variants, ultimately undermining vaccine effectiveness. We argue that, although this is possible, preliminary evidence instead suggests such strategies should slow the rate of viral escape from vaccine or naturally induced immunity. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence of efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution. Twit Text FOAVip Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33795856 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33795856 #FOAvip English Wikipedia <ref>{{Cite pmid|33795856}}</ref> Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination #MMPMID33795856 Cobey S; Larremore DB; Grad YH; Lipsitch M Nat Rev Immunol 2021[May]; 21 (5): 330-335 PMID33795856show ga When vaccines are in limited supply, expanding the number of people who receive some vaccine, such as by halving doses or increasing the interval between doses, can reduce disease and mortality compared with concentrating available vaccine doses in a subset of the population. A corollary of such dose-sparing strategies is that the vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine-escape variants, ultimately undermining vaccine effectiveness. We argue that, although this is possible, preliminary evidence instead suggests such strategies should slow the rate of viral escape from vaccine or naturally induced immunity. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence of efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution. |*Off-Label Use[MESH] |Biological Evolution[MESH] |COVID-19/immunology/*prevention & control[MESH] |Humans[MESH] |Immune Evasion/genetics/immunology[MESH] |SARS-CoV-2/*genetics/*immunology[MESH] |Vaccination/*methods/psychology[MESH]Concerns about SARS-CoV-2 evolution should not hold back efforts to ex(epmc).pdf DeepDyve Pubget Overpricing